1. Home
  2. SNGX vs MFI Comparison

SNGX vs MFI Comparison

Compare SNGX & MFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • MFI
  • Stock Information
  • Founded
  • SNGX 1987
  • MFI 2002
  • Country
  • SNGX United States
  • MFI Hong Kong
  • Employees
  • SNGX N/A
  • MFI N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • MFI
  • Sector
  • SNGX Health Care
  • MFI
  • Exchange
  • SNGX Nasdaq
  • MFI NYSE
  • Market Cap
  • SNGX 7.4M
  • MFI 9.9M
  • IPO Year
  • SNGX 1987
  • MFI 2024
  • Fundamental
  • Price
  • SNGX $2.30
  • MFI $0.69
  • Analyst Decision
  • SNGX
  • MFI
  • Analyst Count
  • SNGX 0
  • MFI 0
  • Target Price
  • SNGX N/A
  • MFI N/A
  • AVG Volume (30 Days)
  • SNGX 618.4K
  • MFI 291.2K
  • Earning Date
  • SNGX 03-14-2025
  • MFI 02-24-2025
  • Dividend Yield
  • SNGX N/A
  • MFI N/A
  • EPS Growth
  • SNGX N/A
  • MFI N/A
  • EPS
  • SNGX N/A
  • MFI N/A
  • Revenue
  • SNGX $364,183.00
  • MFI $3,877,747.00
  • Revenue This Year
  • SNGX N/A
  • MFI N/A
  • Revenue Next Year
  • SNGX $76.64
  • MFI N/A
  • P/E Ratio
  • SNGX N/A
  • MFI N/A
  • Revenue Growth
  • SNGX N/A
  • MFI N/A
  • 52 Week Low
  • SNGX $1.83
  • MFI $0.51
  • 52 Week High
  • SNGX $14.88
  • MFI $14.49
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 37.67
  • MFI N/A
  • Support Level
  • SNGX $2.23
  • MFI N/A
  • Resistance Level
  • SNGX $2.43
  • MFI N/A
  • Average True Range (ATR)
  • SNGX 0.14
  • MFI 0.00
  • MACD
  • SNGX 0.02
  • MFI 0.00
  • Stochastic Oscillator
  • SNGX 29.79
  • MFI 0.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About MFI MF INTERNATIONAL LIMITED

mF International Ltd is a holding company and all of its operations are carried out by Operating Subsidiaries in Hong Kong. It is a financial trading solution provider principally engaged in the development and provision of financial trading solutions. It has experience in providing real-time mission-critical forex, bullion/commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company has provided a wide range of top-notch services, including mF4 Trading Platform, Bridge and Plugins, CRM System, ECN System, Liquidity Solutions, Cross-platform Broker Plus Solution, Social Trading Applications and others.

Share on Social Networks: